Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai October 21, 2026
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA September 24, 2026